Xinqing Lin, Haiyi Deng, Tianqing Chu, Likun Chen, Yilin Yang, Guihuan Qiu, Xiaohong Xie, Yinyin Qin, Ming Liu, Zhanhong Xie, Ming Ouyang, Shiyue Li, Yong Song, Francesco Petrella, Marko Jakopovic, Nikolaos Tsoukalas, Piergiorgio Solli, Taichiro Goto, Yuichi Saito, Chengzhi Zhou
BACKGROUND: Checkpoint inhibitor-related pneumonitis (CIP) induced by immune checkpoint inhibitors (ICIs) is one of the most fatal immune-related adverse events (irAE). However, only limited data are available on rechallenge with ICIs after CIP. We evaluated the efficacy and safety of rechallenge after CIP in patients with advanced lung cancer to identify the potential populations that would benefit. METHODS: We conducted a multicenter retrospective study of advanced lung cancer patients who received further ICI treatment (rechallenge) or did not undergo re-administration after grade ≥1 CIP between May 2017 and May 2021...
November 2022: Translational Lung Cancer Research